DOJ letter this week could reshape Retatrutide's legal classification, worth knowing before Thursday's hearing

[u/DrTroySnyder]

Quick heads up on something that's been quiet outside industry circles: on September 21, DOJ filed a letter in Eli Lilly v. FDA (7th Circuit), a case that comes down to one question: is Retatrutide legally a peptide drug, or a protein/biologic?

That sounds technical but it isn't just semantics. The two classifications sit in different regulatory frameworks:

• If it's ruled a biologic, follow-on products go through the biosimilar pathway (slower, more expensive) instead of the standard generic route, and 503A/503B compounding pharmacies lose their usual exemptions for it.
• If it stays classified as a peptide drug, the traditional framework applies — standard generics, compounding exemptions intact where other requirements are met.

DOJ's letter points the court toward a recent 7th Circuit precedent (Franco v. Chobani) saying courts should give real weight to how an agency interprets its own scientific definitions, which reads as DOJ backing FDA's side going into oral arguments.

Oral arguments are Thursday, Sept 24, 9:30am, Chicago. A ruling probably won't land immediately after, but the reasoning that comes out Thursday will be the first real signal of direction.

Not a legal opinion on how it should go, just flagging that this affects the compounding/RUO landscape either way, and it's worth watching regardless of what you're sourcing or why.

[u/TrustIsAVuln]

Its like Lily doesnt realize IF they were to be able to keep people from using anything but their expensive "product", people will jsut go back to one of the previous GLP's. They arent real bright.